A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury
10.1016/j.apsb.2020.11.002
- Author:
Tailin HE
1
;
Jialin SHANG
2
;
Chenglong GAO
1
;
Xin GUAN
1
;
Yingyi CHEN
2
;
Liwen ZHU
3
;
Luyong ZHANG
1
;
Cunjin ZHANG
3
;
Jian ZHANG
2
;
Tao PANG
1
Author Information
1. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing 210009, China.
2. Medicinal Bioinformatics Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
3. Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.
- Publication Type:Journal Article
- Keywords:
Deacetylation;
EZH2;
FOXC1;
Ischemic stroke;
Macrophage;
Microglia;
Neuroinflammation;
SIRT6 activator
- From:
Acta Pharmaceutica Sinica B
2021;11(3):708-726
- CountryChina
- Language:English
-
Abstract:
Ischemic stroke is the second leading cause of death worldwide with limited medications and neuroinflammation was recognized as a critical player in the progression of stroke, but how to control the overactive neuroinflammation is still a long-standing challenge. Here, we designed a novel SIRT6 activator MDL-811 which remarkably inhibited inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages and primary mouse microglia, which were abolished by silencing SIRT6. RNA-seq screening identified the forkhead box C1 (
